Additional Proxy Soliciting Materials (definitive) (defa14a)
March 17 2017 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant
þ
Filed by a Party other than the Registrant
o
Check the appropriate box:
o
Preliminary Proxy
Statement
o
Confidential,
For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))
o
Definitive
Proxy Statement
þ
Definitive
Additional Materials
o
Soliciting
Material under Rule 14a-12
Anavex Life Sciences Corp.
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
þ
No
fee required
o
Fee computed
on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction
applies:
(2) Aggregate number of securities to which transaction
applies:
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
o
Fee paid
previously with preliminary materials.
o
Check box
if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its
filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
SUPPLEMENT TO DEFINITIVE PROXY STATEMENT
The following disclosure supplements
the definitive proxy statement filed by Anavex Life Sciences Corp. (the “Company”) with the Securities and Exchange
Commission (the “SEC”) on March 10, 2017 (the “Definitive Proxy Statement”). This supplemental information
should be read in conjunction with the Definitive Proxy Statement, which should be read in its entirety. The information set forth
in the Definitive Proxy Statement remains unchanged and is incorporated herein by reference as relevant to the items set forth
below.
On March 10, 2017,
the Company mailed the letter attached hereto as Attachment 1 to its stockholders, along with the Definitive Proxy Statement and
documents ancillary thereto.
Supplemental Information Regarding
Proposal 2, the Amendment of the Company’s Articles of Incorporation to Authorize up to 10,000,000 Shares of Blank-Check
Preferred Stock
At our 2017 Annual Meeting
of Stockholders, to be held on Tuesday, April 18, 2017, our stockholders will vote on an amendment to amend the Company’s
Articles of Incorporation to authorize up to 10,000,000 shares of blank-check preferred stock. The Definitive Proxy Statement is
amended to add Exhibit A to the Definitive Proxy Statement, which was originally included in the preliminary Proxy Statement filed
on February 27, 2017 with the Securities and Exchange Commission. All other items of the Proxy Statement are incorporated herein
by reference without changes.
The Board unanimously recommends
a vote “FOR” approval of Proposal 2.
Important Notice Regarding the Availability
of Proxy Materials for the Annual Meeting of Stockholders to Be Held on Tuesday, April 18, 2017 at the offices of Nasdaq MarketSite
at 4 Times Square, New York, NY 10036.
Copies of this proxy statement and proxy
materials ancillary hereto, and the 2016 Annual Report may be found on our website at
www.anavex.com
and at
www.proxyvote.com
.
Dea
r
Sha
r
eho
l
de
r,
I
a
m
p
l
ea
s
e
d
to i
nv
ite
yo
u to
a
tt
en
d
ou
r
201
7
Annua
l
G
ene
r
a
l
M
ee
ti
n
g
o
f
S
t
o
ck
ho
l
de
rs
(t
h
e “
M
ee
ti
ng
”),
wh
i
c
h
w
ill
b
e
he
ld
o
n
Tuesday
,
Ap
ril
18
,
2017
,
10
:
0
0
a
.
m
., l
o
c
a
l
ti
m
e
,
a
t
t
h
e
o
ffic
e
s
o
f
Nasda
q
M
a
r
ke
t
S
it
e
,
4
T
i
m
e
s
Squa
r
e
,
Ne
w
Yo
r
k
,
N
Y
1003
6
.
You
r
pa
rti
c
i
pa
ti
o
n
in t
h
is
m
e
e
ti
n
g
is
ve
ry i
m
po
rt
an
t
an
d
w
e
as
k
t
ha
t
yo
u r
ev
i
e
w
t
h
e
en
cl
o
s
e
d
p
r
ox
y
s
t
a
t
e
m
en
t,
wh
i
c
h
g
i
ve
s
i
m
po
rt
an
t
i
n
f
o
r
m
a
ti
o
n
r
ega
r
d
i
n
g
t
h
e
bus
i
nes
s
to
b
e
condu
ct
e
d
at
t
h
e
M
ee
ti
ng
.
You
r
vo
te is
ve
ry
i
m
po
rt
an
t
to
u
s
an
d
w
e
s
tr
ong
ly
encou
r
ag
e
yo
u to
exe
r
c
i
s
e
you
r ri
gh
t to
vo
te
o
n t
h
e
m
a
tt
e
rs
se
t f
o
rth in t
h
e
p
r
ox
y
s
t
a
t
e
m
en
t.
O
u
r
Boa
rd
o
f
D
ir
ec
t
o
rs
unan
i
m
ous
ly
r
eco
mm
end
s
t
ha
t
yo
u
vo
te
in f
avo
r
o
f
a
ll
o
f t
h
e
p
r
opo
s
e
d
r
eso
l
u
ti
ons
.
Yo
u
ca
n
vo
te
us
i
n
g
an
y
on
e
o
f
t
h
e f
o
ll
ow
i
n
g
m
e
t
hod
s:
|
1)
|
E
l
ec
tr
on
i
ca
lly
b
y
sub
m
itti
n
g
you
r
vo
te
a
t
www
.
p
r
oxyvo
t
e
.
co
m
us
i
n
g t
h
e
con
tr
o
l
nu
m
ber
fr
o
m t
h
e
en
cl
o
s
e
d
p
r
ox
y c
a
r
d
.
|
|
2)
|
B
y t
e
l
ephon
e
b
y
ca
lli
n
g
1
-
800
-
690
-
6903
.
P
l
eas
e
hav
e
you
r
p
r
ox
y
ca
rd
ava
il
ab
l
e
.
|
|
3)
|
B
y
M
a
il
b
y
s
i
gn
i
n
g
an
d r
e
t
u
r
n
i
n
g
t
h
e
p
r
ox
y
ca
rd
p
r
ov
i
de
d
he
r
e
in as
soo
n
a
s
poss
i
b
l
e
.
|
Th
e
p
r
ox
y
ca
rd
m
us
t
b
e
r
ece
i
ve
d
n
o
l
a
t
e
r t
ha
n
Ap
ril
14
,
2017
.
P
l
eas
e
a
ll
o
w
adequa
te ti
m
e f
o
r
m
a
ili
ng
.
|
4)
|
In
Pe
rs
o
n
S
t
ockho
l
de
rs
o
f r
eco
rd
an
d
bene
fi
c
i
a
l
s
t
ockho
l
de
rs
w
ith
sha
r
e
s
he
ld
b
y a
ban
k,
b
r
oke
r
o
r
o
t
he
r
no
m
i
ne
e
m
a
y
vo
te
in
pe
rs
o
n
a
t
t
h
e
M
ee
ti
ng
.
P
l
ea
se
no
t
e
,
howeve
r, t
ha
t if
you
r
sha
r
e
s
a
re
he
ld
b
y a
b
r
oke
r,
ban
k
o
r
o
t
he
r
no
m
i
ne
e
an
d
yo
u
w
ish
to
vo
te
a
t t
h
e
M
ee
ti
ng
,
yo
u
w
ill
no
t
b
e
pe
r
m
itt
e
d
to
vo
te in
pe
rs
o
n
a
t t
h
e
M
ee
ti
n
g
un
l
e
ss
yo
u
first
ob
t
a
in a l
ega
l
p
r
ox
y iss
ue
d
in
you
r
na
m
e
fr
o
m t
h
e r
e
c
o
rd
ho
l
de
r.
|
Fo
r
add
iti
ona
l
vo
ti
n
g
ass
i
s
t
anc
e
o
r
ques
ti
ons
,
p
l
eas
e
ca
ll
ou
r
p
r
ox
y
so
li
c
it
a
ti
o
n
agen
t,
K
i
ngsda
le
Adv
i
so
rs
b
y
t
e
l
ephon
e
a
t
1
-
800
-
775
-
315
9
o
r t
h
r
oug
h
e
m
a
il
at con
t
ac
t
us
@
k
i
ngsda
l
eadv
is
o
rs.c
o
m
.
O
n
beha
lf
o
f
Anavex
,
t
han
k
yo
u f
o
r
you
r
suppo
rt
a
s
sha
r
eho
l
de
r
s
.
W
e l
oo
k f
o
r
wa
rd
to
bu
il
d
i
n
g
o
n
ou
r
pas
t
acco
m
p
li
sh
m
en
ts
w
ith
you
r
con
ti
nue
d
suppo
rt,
an
d
w
e
t
han
k
yo
u in
advanc
e
f
o
r
you
r
vo
t
e
.
Yours
tr
u
ly
Christopher
U Missling
Ch
ri
s
t
ophe
r
U
.
M
is
s
li
ng
,
Ph
D
Ch
i
e
f
Execu
ti
v
e
O
ffi
ce
r
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024